Anti-Mesothelin Rabbit Polyclonal Antibody (WB)
Anti-Mesothelin Rabbit Polyclonal Antibody (WB)
General information
| Cat. No. | ：SB-GB111016 |
| Size | ：100 uL |
| Protein full name | ：Mesothelin |
| Synonym | ：Pre-pro-megakaryocyte-potentiating factor, Megakaryocyte-potentiating factor, MPF, Msln, Mes, CAK1, SMR, SMRP, MAN |
| Immunogen | ：KLH conjugated Synthetic peptide corresponding to Mouse Mesothelin |
| Isotype | ：IgG |
| Purity | ：Affinity purification |
| Predicted MW. | ：69KDa |
| Observed MW. | ：49KDa |
| Uniprot ID | ：Q61468, Q9ERA7 |
| Long Term Storage | ：-20 ℃ or below |
| Shipping Condition | ：Dry Ice |
| Storage Buffer | ：PBS with 0.02% sodium azide,100 μg/ml BSA and 50% glycerol. |
Application
| Applications | Species | Dilution | Positive Tissue |
| WB | Mouse, Rat | 1: 500-1: 1000 | thymus heart lung testis |
Description
Mesothelin is a glycosyl-phosphatidylinositol-anchored glycoprotein present on the cell surface of various human solid tumors. It is expressed on pleural and peritoneal mesothelial cells, but not in other non-neoplastic tissues. The mesothelin gene encodes a 6 9-71kDa precursor protein that is processed to a 40kDa membrane-bound protein termed mesothelin and a 31kDa shed fragment called megakaryocyte-potentiating factor (MPF) that is released from the cell. Mesothelin is a tumor differentiation antigen present at low levels on a restricted set of normal adult tissues ( eg mesothelium), and is expressed at high levels in mesotheliomas, as well as ovarian, pancreatic, and lung cancers. Mesothelin may be a new target for immunotherapy.
 |
Western blot analysis of mesothelin（CA125) (GB111016) at dilution of 1: 500 |
Antigen Characterization
- Type: Primary
- Application: ELISA (Enzyme-Linked Immunosorbent Assay),Western Blot,Immunohistochemistry,Flow Cytometry
- Species: Human
- Recombinant: Yes
Human Diseases
- Mesothelioma: High levels of mesothelin are associated with this cancer, and its expression is used as a diagnostic marker.
- Ovarian Cancer: Overexpression correlates with poor prognosis and is involved in peritoneal implantation of cancer cells.
- Pancreatic Cancer: Nearly all pancreatic cancers express mesothelin, making it a potential target for therapy.
- Lung Cancer: Mesothelin is expressed in a significant percentage of lung adenocarcinomas.
- Acute Myeloid Leukemia (AML): Recently identified as overexpressed in some hematological malignancies, presenting new therapeutic opportunities.
Cellular Signaling Pathways
- PI3K/Akt Pathway: Mesothelin activation can lead to cell proliferation and survival through this pathway.
- MAPK/ERK Pathway: Involved in cell growth and differentiation; mesothelin can activate this pathway, promoting tumorigenesis.
- Wnt Signaling Pathway: Mesothelin expression can be regulated by Wnt signaling, which is crucial in many cancers.
- MMP Activation: Soluble mesothelin can trigger matrix metalloproteinases (MMP-7), enhancing migration and invasion of cancer cells.
- NFκB Pathway: Overexpression of mesothelin can lead to NFκB activation, contributing to cancer cell survival and resistance to apoptosis.
Aliases for MSLN Gene
References
- Zhan, Jingyu, et al. “Structures of Cancer Antigen Mesothelin and Its Complexes with Therapeutic Antibodies.” Cancer Research Communications, U.S. National Library of Medicine, 1 Feb. 2023, pmc.ncbi.nlm.nih.gov/articles/PMC10035497/.
- Hassan, Raffit, Tapan Bera, et al. “Mesothelina New Target for Immunotherapy.” American Association for Cancer Research, American Association for Cancer Research, 24 June 2004, aacrjournals.org/clincancerres/article/10/12/3937/182171/MesothelinA-New-Target-for-Immunotherapy.
- Faust, Joshua R, et al. “Mesothelin: An Immunotherapeutic Target beyond Solid Tumors.” Cancers, U.S. National Library of Medicine, 18 Mar. 2022, www.ncbi.nlm.nih.gov/pmc/articles/PMC8946840/.
- Zhang, Zhiwei, et al. “Modified Car T Cells Targeting Membrane-Proximal Epitope of Mesothelin Enhances the Antitumor Function against Large Solid Tumor.” Nature News, Nature Publishing Group, 17 June 2019, www.nature.com/articles/s41419-019-1711-1.
- Lv, Jiang, and Peng Li. “Mesothelin as a Biomarker for Targeted Therapy - Biomarker Research.” BioMed Central, BioMed Central, 23 Aug. 2019, biomarkerres.biomedcentral.com/articles/10.1186/s40364-019-0169-8.
